英文摘要 |
The bone is the most common site for distant metastasis in breast cancer patients. Clinically, a bone scintigraphy is most commonly utilized to assess the presence of bone metastases, by intravenous injection of technetium 99m-methyl diphosphonate (Tc-99m MDP) into the human body. When cancer cells metastasize to the bone, they destroy the bone tissue and stimulate bone repair of the affected area. The new bone absorbs higher amounts of calcium and phosphate and shows increased radioactivity on bone scintigraphy. However, when breast cancer cells invade the bone, they stimulate the proliferation of osteoclasts, which may be less obvious on bone scintigraphy images. In 2018, a 48-year-old woman was diagnosed with breast cancer and underwent total mastectomy, and axillary lymph node dissection. No bone metastases were found in the regular bone scintigraphy performed every three months to one year. In June 2020, the level of CA-153 was found to be elevated. A positron emission tomography/computed tomography (PET/CT) scan was performed in July. Bone metastases were discovered in the left clavicle, sternum, left sixth rib, seventh thoracic vertebra, right scapula, fourth lumbar, left and right pelvis, ilium, and left femur. The bone scintigraphy is a planar image that is prone to overlap due to the relative positions. Because of the proliferation of osteoclasts, the bones absorb less Tc-99m MDP, resulting in less obvious manifestations in the bone scintigraphy images that were not easily detected. For instance, the clavicle and the ribs, the sternum and the thoracic vertebrae, and the scapula and the ribs can easily overlap. The PET/CT scan can help diagnosis of osteolytic bone metastases in breast cancer. |